This is a phase 2, open-label, umbrella study, with the purpose to evaluate the therapeutic
efficacy and safety of chemoradiotherapy in combination with immunotherapy and/or targeted
treatment in high-risk locoregionally advanced nasopharyngeal carcinoma. The specific
grouping of patients' depends on the SYSUCC immune subtyping based on 100+ gene panel
testing.